Inhibrx reports 20% response rate for ozekibart in CRC trial

Inhibrx Biosciences reported interim Phase 1/2 data for ozekibart in metastatic colorectal cancer, with a 20% objective response rate, 5.5-month median progression-free survival, and 87% disease control rate. The company also said it will meet with the FDA in 2H 2026 to discuss a first-line registrational trial and potential accelerated pathways, while separately filing a BLA for ozekibart in conventional chondrosarcoma. Stifel reiterated a Buy rating and $150 price target, reinforcing a constructive analyst view despite the stock already rising more than 620% over the past year.

Analysis

The market is likely to focus less on the headline efficacy and more on the shape of the commercial pathway. A 20% response rate in a heavily pretreated population is meaningful because it de-risks the mechanism in a setting where incremental efficacy is usually hard to show, but the real inflection for valuation is whether management can translate this into a cleaner regulatory narrative: accelerated approval in a narrow refractory label versus a larger, slower first-line trial. That creates a classic biotech bifurcation where the stock can remain supported on data quality even if the eventual peak-sales case does not expand as quickly as bulls want.

Second-order, the most important read-through is to the competitive set in late-line colorectal cancer, where many programs can produce tolerable safety but fail on durability or liver-metastasis subsets. The lack of meaningful hepatotoxicity matters because it widens the addressable population and reduces physician hesitation in patients with compromised baseline burden, which can improve enrollment velocity for the next study and lower commercialization friction. That said, the current setup is vulnerable to the usual post-data air pocket: once a phase-1/2 signal becomes consensus, the stock often prices a perfect regulatory sequence months before any FDA interaction actually converts into a label.

The contrarian angle is that the market may be overpaying for optionality embedded in multiple indications at once. If the chondrosarcoma filing absorbs management attention and the colorectal program is pushed toward a longer registrational path, near-term catalysts could become sequencing risk rather than upside surprise. In that scenario, the stock’s recent vertical move leaves little room for any dilution, trial design delay, or a narrower-than-hoped label, even if the science remains intact.

From a trading perspective, this is more attractive as a catalyst-driven volatility expression than as an outright long at current levels. The cleanest near-term setup is to own upside into FDA-meeting headlines while respecting that the risk/reward deteriorates quickly once the next step becomes a study-design discussion rather than a binary data event. The data are good enough to sustain institutional interest, but not yet strong enough to eliminate financing and timeline risk.

Key Decisions for Investors

• Buy INBX on pullbacks, not strength, and use the next 4-8 weeks to accumulate only if the stock retraces 10-15% from the post-data level; risk/reward improves materially because the story is already discounted as a multi-catalyst winner.
• For event exposure, consider INBX Jan/Apr 2027 call spreads instead of stock; upside is tied to FDA pathway clarity over 6-12 months, while premium outlay limits damage if regulatory timing slips.
• Fade excessive enthusiasm by pairing long INBX against a basket of late-stage biotech names with near-term dilution risk; the thesis is that INBX’s multiple now embeds more optimism than most peers, but the next leg requires execution, not just data.
• If long shares, hedge with a tight trailing stop or short-dated puts into the planned FDA meeting in 2H26; this is where binary reversal risk rises if the agency pushes back on endpoint selection or line of therapy.
• Monitor for secondary offering risk over the next 1-2 quarters; if management taps equity after the stock’s run, treat any offering weakness as a better re-entry than chasing momentum.